

Effects of 1,25(OH)₂D₃, 25OHD₃, and EB1089 on cell growth and Vitamin D receptor mRNA and 1 α -hydroxylase mRNA expression in primary cultures of the canine prostate[☆]

S. Kunakornsawat^a, T.J. Rosol^a, C.C. Capen^a, J.L. Omdahl^b, B.E. Leroy^a, N. Inpanbutr^{a,*}

^a Department of Veterinary Biosciences, The Ohio State University, 1900 Coffey Road, Columbus, OH 43210, USA

^b Department of Biochemistry and Molecular Biology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA

Abstract

The aim of this study was to investigate effects of 1,25(OH)₂D₃ (calcitriol), 25OHD₃, and EB1089 on cell growth and on Vitamin D receptor (VDR) mRNA and 1 α -hydroxylase (1 α -OHase) mRNA expression in normal canine prostatic primary cultures. Canine prostatic epithelial cells were isolated, cultured, and treated with vehicle (ethanol), calcitriol, 25OHD₃, and EB1089 at 10⁻⁹ and 10⁻⁷ M. The VDR was present in epithelial and stromal cells of the canine prostate gland. 1,25(OH)₂D₃, 25OHD₃, and EB1089 inhibited epithelial cell growth at 10⁻⁷ M compared to vehicle-treated controls [calcitriol ($P < 0.01$), EB1089 ($P < 0.01$), and 25OHD₃ ($P < 0.05$)]. Epithelial cells treated with calcitriol and EB1089 at 10⁻⁷ M had slightly increased VDR mRNA expression (0.2–0.3-fold) at 6 and 12 h compared to controls. There was no difference in 1 α -OHase mRNA expression in epithelial cells treated with these three compounds. 1,25(OH)₂D₃ and its analogs may be effective antiproliferative agents of epithelial cells in certain types of prostate cancer.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: Canine prostate primary culture; 1,25(OH)₂D₃; Calcitriol; 25OHD₃; EB1089; Antiproliferative effects; Vitamin D receptor; 1 α -Hydroxylase; Primary culture

1. Introduction

Low plasma levels of 1,25(OH)₂D₃ (calcitriol) and its analogs have been correlated to increased risk of human prostate cancer [1]. Several studies have demonstrated that 1,25(OH)₂D₃ and its analogs could affect the regulation of growth and differentiation in human prostate cancer mediated through the 1,25(OH)₂D₃-receptor (VDR) [2]. Although increasing data indicate a role for 1,25(OH)₂D₃ in prostate cancer, little is known about the role of this hormone in the canine prostate cells. The canine prostate is a valuable animal model for the study of prostate pathobiology and for pharmaceutical research due to its high incidence of benign prostatic hyperplasia. Spontaneous prostatic intraepithelial neoplasia also has been reported in dogs [3]. Prostatic intraepithelial neoplasia is the most likely precursor of human prostate cancer. The dog prostate can serve as a useful model for examining factors that modulate prostatic intraepithelial

neoplasia and prostate cancer progression. However, the effects of calcitriol and its analogs has not been reported on the canine prostate. The objective of this study was to investigate effects of 1,25(OH)₂D₃, 25OHD₃, and EB1089 on cell growth and on VDR mRNA and 1 α -OHase mRNA expression in normal canine prostatic primary cultures.

2. Materials and methods

2.1. Vitamin D and its analogs

1,25(OH)₂D₃, 25OHD₃, and EB1089 were gifts from Dr. L. Binderup (Leo Pharmaceutical Products, Ballerup, Denmark).

2.2. Plasmid DNA of VDR and 1-OHase

Plasmid DNA of human VDR and pig 1 α -OHase were from Dr. Omdahl's laboratory. PRSV-hVDR was full-length cDNA encoding human VDR, in pRSVN vector. The full length was released with EcoR I and Bam HI. P1OHpcDNA3 was full-length cDNA encoding pig 1 α -OHase, in pcDNA3 vector. The full length was released with Not I and Xho I.

[☆] Presented at the 12th Workshop on Vitamin D (Maastricht, The Netherlands, 6–10 July 2003).

* Corresponding author. Tel.: +1-614-292-8641; fax: +1-614-292-7599.
E-mail address: inpanbutr.1@osu.edu (N. Inpanbutr).

2.3. Cell culture

Tissue samples were obtained from normal adult male beagles. Following 3–4 h of 0.5% type I collagenase digestion of the minced tissue in DMEM/F12 with 10% FBS. Epithelial cells were derived by changing medium to low calcium Keratinocyte-SFM (Gibco BRL, NY) supplemented with 10 ng/ml of epidermal growth factor (EGF), 10 µg/ml of bovine pituitary extract (BPE), and 50 µg/ml of gentamicin to selectively enrich the epithelial cell population [4].

2.4. Cell growth assay

Cells were seeded at density of 10^5 cells per well in 6-well culture plates (Becton Dickinson, NJ) and grown for 24 h before starting experiments (day 0). Medium containing vehicle (ethanol), 1,25(OH)₂D₃, 25OHD₃, and EB1089 were added at concentrations 10^{-9} and 10^{-7} M and was changed every day for up to a week. Each experiment was run in triplicate. At the end of experiments cellular DNA was isolated with 4 M guanidine isothiocyanate (GITC) containing 0.5% sodium lauroyl sarcosine and 25 mM sodium citrate.

2.5. RNA assay

Epithelial cells (2×10^6 cells/ml) were plated in 100-mm tissue culture dishes (Becton Dickinson, NJ) and grown to near confluence in Keratinocyte-SFM medium containing 10 ng/ml of EGF and 10 µg/ml of BPE. Cells were treated with vehicle, 1,25(OH)₂D₃, 25(OH)D₃, and EB1089 at 10^{-7} M for 0, 1, 3, 6, 12, 24 h. Cells were washed (PBS), trypsinized, and stored at -80°C until assayed by Northern blot analysis.

2.6. Fluorescence DNA analysis

DNA content of cell lysates was measured at 450 nm on an IDEXX fluorimeter (IDEXX Laboratories Inc., ME) using a 96-well black U-bottom Microfluor plate reader (Dynatech Labs, UK) and Hoechst 33258 dye (Hoefer Scientific Instruments, CA). Samples were aliquoted into 100 µl TNE buffer (10 mM Tris pH 8.0, 0.5 mM EDTA, 0.25 NaCl), calf thymus DNA (100 µg/ml) served as a calibration control [5].

2.7. Total RNA isolation and Northern blot analysis

Total RNA was isolated by using the Purescript[®] RNA isolation kit (Gentra systems, MN). Equal amounts of each RNA sample (20 µg) were separated on a 1% formaldehyde-agarose gel, transferred to a nylon membrane (Poll Biosupport, East Hills, NY), and crosslinked with UV light (Stratalinker, CA). Northern blots were hybridized with ³²P-labeled human VDR or pig 1α-OHase cDNA probes (NEN Life Science Products Inc., MA). The radioactivity was measured and quantitated with a Phosphorimager (425F-120, Molecular Dynamics Inc., CA), the

membrane was then stripped and hybridized with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe to normalize for RNA loading [5].

2.8. Immunohistochemistry

According to our protocol [5], the staining was done by incubating with 5% normal goat serum (NGS) in PBS for 30 min, primary antibody—rat monoclonal antibody against VDR (Chemicon International Inc., CA) 1:100 at 4°C overnight, secondary antibody—biotinylated goat anti-rat immunoglobulin G at 1:20 in PBS for 30 min, avidin-biotin-peroxidase complex (Kirkegaard & Perry Laboratories, MD) 1:100 in 1% NGS in PBS for 30 min, and color developed with 0.05% DAB and 0.01% hydrogen peroxide in 0.05 M Tris buffer for 5 min, washed, mounted with aqua-Mount and visualized by light microscopy.

2.9. Statistical analysis

Numerical data for the DNA concentrations were analyzed by one-way analysis of variance (ANOVA) and Turkey's mean separation test with the level of significance at $P < 0.05$, $P < 0.01$, or $P < 0.001$ using the Instat program (Graph PAD software (version 3.01) Inc., San Diego, CA). The results were expressed as the mean \pm standard error of the mean (S.E.M.) ($n = 3$). Experiments were performed multiple times (as noted in Section 3), each time with cells from separate dogs.

3. Results

The VDR was present in epithelial and stromal cells of the canine prostate gland (Fig. 1). There was a significant decrease in the proliferation of epithelial cells treated with 10^{-7} M 1,25(OH)₂D₃, 25OHD₃, and EB1089 compared to vehicle-treated controls (Fig. 2). Epithelial cells treated with 1,25(OH)₂D₃ and EB1089 at 10^{-7} M had slightly




Fig. 1. Immunoperoxidase labeling of 1,25(OH)₂D₃ receptor (VDR) with monoclonal anti-VDR (A) demonstrated positive labeling of all nuclei of normal canine prostatic epithelial and stromal cells (arrowheads), (B) control section was treated with non-specific antiserum in place of a specific primary antibody. Magnification: 300 \times .




Fig. 2. Growth of normal canine prostate epithelial cells. Cells were treated with 1,25(OH)₂D₃, 25OHD₃, and EB1089 at 10⁻⁷ M. DNA content of epithelial cells was determined after 7 days. The mean values of triplicate samples ± S.E.M. are presented. Significant differences marked with **P* < 0.05, ***P* < 0.01 as compared to vehicle-treated controls.




Fig. 3. VDR mRNA expression. VDR mRNA was detectable at all time points (0, 3, 6, 12, and 24 h) in epithelial cells treated with vehicle, 1,25(OH)₂D₃, 25OHD₃, and EB1089. Epithelial cells treated with 1,25(OH)₂D₃ and EB1089 at 10⁻⁷ M had slightly increased VDR mRNA expression at 6 and 12 h compared to vehicle-treated controls.

increased VDR mRNA expression at 6 and 12 h compared to vehicle-treated controls (Fig. 3). There was no difference in the expression of 1 α -OHase mRNA in epithelial cells treated with these three compounds (Fig. 4).

4. Discussion

We have demonstrated that 1,25(OH)₂D₃, EB1089, and 25OHD₃ inhibited epithelial cell growth of the normal canine prostate. The inhibitory effect of 1,25(OH)₂D₃ on epithelial cells also have been reported in normal human prostate primary cultures [6]. The greater inhibition of cell growth by EB1089 has been correlated with the higher affinity for VDR-binding compared to 1,25(OH)₂D₃ in human prostatic cancer cells [7]. These data suggest that the potency of these compounds on inhibiting cell growth is related to the level of VDR and/or the affinity of 1,25(OH)₂D₃ for VDR-binding. A slight increase in VDR mRNA level was found at 6 and 12 h in epithelial cells treated with 1,25(OH)₂D₃ and EB1089. Our results support other studies [2] that the inhibitory action of 1,25(OH)₂D₃ and its




Fig. 4. 1 α -OHase mRNA expression. 1 α -OHase mRNA was detectable at all time points (0, 3, 6, 12, and 24 h) in both epithelial cells treated with vehicle, 1,25(OH)₂D₃, 25OHD₃, and EB1089. There was no difference in the expression of 1 α -OHase mRNA in epithelial cells treated with these three compounds at 10⁻⁷ M compared to vehicle-treated controls.

analogs on primary culture of canine prostatic epithelial cells is mediated through the VDR.

Human prostate cell lines (DU 145, PC-3) exhibited 1 α -OHase activity and synthesized 1,25(OH)₂D₃ intracellularly from 25OHD₃ [8]. The extra-renal production of this hormone points to an autocrine/paracrine role for 1,25(OH)₂D₃ where it could locally modulate cell growth. In human prostate primary culture, 25OHD₃ has been shown to inhibit the proliferation of epithelial cells [9]. Similarly, we demonstrated that 25OHD₃ inhibited the growth of normal canine prostatic epithelial cells. These data suggest that the inhibitory effect of 25OHD₃ on prostatic epithelial cells may be due to local conversion of 25OHD₃ to 1,25(OH)₂D₃.

Our results were consistent with other studies [10] that reported 1,25(OH)₂D₃ and its analogs did not affect the levels of extrarenal 1 α -OHase. This suggests that the resistance of canine prostate 1 α -OHase to 1,25(OH)₂D₃ occurs at the mRNA level. Therefore, the most likely explanation for the inhibition of extrarenal 1 α -OHase involves different regulatory pathways from renal 1 α -OHase, which are less sensitive to autoregulation by 1,25(OH)₂D₃ [11]. Our results demonstrated that canine prostate epithelial cells' response to calcitriol, 25OHD₃, and EB1089 is similar to that of human prostate epithelial cells. This supports our suggestion that canine prostate can be a useful animal model for the study of diseases of the prostate gland.

5. Conclusion

The VDR was present in epithelial and stromal cells of the normal canine prostate gland. There was a significant decrease in the proliferation of epithelial cells treated with 1,25(OH)₂D₃, 25OHD₃, and EB1089 at 10⁻⁷ M compared to vehicle-treated controls. Epithelial cells treated with 1,25(OH)₂D₃ and EB1089 at 10⁻⁷ M had slightly increased VDR mRNA expression at 6 and 12 h compared to vehicle-treated controls. There was no difference in the expression of 1α-OHase mRNA in epithelial cells treated with these three compounds.

Acknowledgements

This work was supported by State of Ohio Canine Research Funds Grant No. 520122 and the Royal Thai Government Scholarship. We thank Dr. L. Binderup (Leo Pharmaceutical Products, Ballerup, Denmark) for the gifts of 1,25(OH)₂D₃, 25OHD₃, and EB1089.

References

- [1] C.L. Hanchette, G.G. Schwartz, Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation, *Cancer* 70 (1992) 2861–2869.
- [2] G.J. Miller, G.E. Stapleton, J.A. Ferrara, M.S. Lucia, S. Pfister, T.E. Hedlund, P. Upandhya, The human prostate carcinoma line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D₃, *Cancer Res.* 52 (1992) 515–520.
- [3] D.J. Waters, D.G. Bostwick, Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate, *J. Urol.* 157 (1997) 713–716.
- [4] E.A.G. Blomme, Y.L.K. Sugimoto, Y.C. Lin, C.C. Capen, T.J. Rosol, Stromal and epithelial cells of the canine prostate express parathyroid hormone-related protein, but not the PTH/PTHrP receptor, *Prostate* 36 (1998) 110–120.
- [5] S. Kunakornsawat, C.C. Capen, T.J. Rosol, R. Middleton, S.S. Hanah, N. Inpanbutr, Effects of 1,25-dihydroxyvitamin D₃, EB1089, and analog V on PTHrP production, PTHrP mRNA expression, and cell growth in SCC S/88 cells, *Anticancer Res.* 21 (5) (2001) 10–18.
- [6] D. Krill, J. Stoner, B.R. Konety, M.J. Becich, R.H. Getzenberg, Differential effects of Vitamin D on normal human prostate epithelial and stromal cells in primary culture, *Urology* 54 (1999) 171–177.
- [7] X. Wang, X. Chen, J. Akhter, D.L. Morris, The in vitro effect of Vitamin D₃ analogue EB-1089 on a human prostate cancer cell line (PC-3), *Br. J. Urol.* 80 (1997) 260–262.
- [8] G.G. Schwartz, L.W. Whitlatch, T.C. Chen, B.L. Lokeshwar, M.F. Holick, Human prostate cells synthesize 1,25-dihydroxyvitamin D₃ from 25-hydroxyvitamin D₃, *Cancer Epidemiol. Biomarkers Prev.* 7 (1998) 391–395.
- [9] A.M. Barreto, G.G. Schwartz, R. Woodruff, S.D. Cramer, 25-Hydroxyvitamin D₃, the prohormone of 1,25-dihydroxyvitamin D₃, inhibits the proliferation of primary prostatic epithelial cells, *Cancer Epidemiol. Biomarkers Prev.* 9 (2000) 265–270.
- [10] G. Jones, H. Ramshaw, A. Zhang, R. Cook, V. Byford, J. White, M. Petkovich, Expression and activity of Vitamin D-metabolizing cytochrome P450s (CYP1α and CYP24) in human nonsmall cell lung carcinomas, *Endocrinology* 140 (1999) 3303–3310.
- [11] M. Hewison, D. Zehnder, R. Bland, P.M. Stewart, 1α-hydroxylase and the action of Vitamin D, *J. Mol. Endocrinol.* 25 (2000) 141–148.